The compound of claim 3, wherein said compound is 22J ((R)-N-(3-(3-(trifluoromethyl)phenyl)propyl)-1-(1-naphthyl)ethylamine) or a pharmaceutically acceptable salt or complex thereof.

The method of claim 21, wherein said compound is 22J ((R)-N-(3-(3-(trifluoromethyl)phenyl)propyl)-1-(1-naphthyl)ethylamine) or a pharmaceutically acceptable salt or complex thereof.

The compound of claim 6, wherein R.sub.2 is either naphthyl or said phenyl having 1 to 5 substituents; and R.sub.3 is either naphthyl or said phenyl optionally substituted with 1 to 5 substituents.

The compound of claim 29, wherein said compound has the following formula: ##STR27## or a pharmaceutically acceptable acid addition salt or complex thereof.

The compound of claim 73, wherein said compound causes an increase in (Ca.sup.2+).sub.i with an EC.sub.50 less than or equal to 5 .mu.M as determined by measuring (Ca.sup.2+).sub.i in bovine parathyroid cells loaded with fura-2 using the Cytosolic Ca.sup.2+ Cell Assay. view more

The pharmaceutical composition of claim 83, wherein alk is n-propylene.

The method of claim 9 wherein said method reduces parathyroid hormone level in said patient.

The method of claim 44, wherein alk is n-propylene.

A method of modulating parathyroid hormone secretion in a patient who would benefit from such treatment comprising administering an effective amount of a compound of the formula: ##STR26## wherein alk is a straight or branched chain alkylene of 0-6 carbon atoms: R.sub.1 is an alkyl radical of 1-3 carbon atoms or a haloalkyl radical of 1-3 carbon atoms substituted with 1-7 halogen atoms: R.sub.2 and R.sub.3 are each independently monocyclic or bicyclic aryl or cycloalkyl radicals of 5-7 ring member carbon atoms, which are optionally substituted with 1-5 radicals of alkyl of 1-3 carbon atoms, haloalkyl of 1-3 carbon atoms substituted with 1-7 halogen atoms, alkoxy of 1-3 carbon atoms, halogen, nitro, amino, alkylamino of 1-3 carbon atoms, amido, alkylamido of 1-3 carbon atoms, cyano, hydroxy, acyl of 2-4 carbon atoms, hydroxyalkyl of 1-3 carbon atoms, or thioalkyl of 1-3 carbon atoms; or a pharmaceutically acceptable salt thereof. view more

A method of treating hyperparathyroidism comprising the step of administering to a patient an effective amount of a compound of the formula: ##STR29## wherein alk is a straight or branched chain alkylene of 0-6 carbon atoms: R.sub.1 is an alkyl radical of 1-3 carbon atoms or a haloalkyl radical of 1-3 carbon atoms substituted with 1-7 halogen atoms: R.sub.2 and R.sub.3 are each independently monocyclic or bicyclic aryl or cycloalkyl radicals of 5-7 ring member carbon atoms, which are optionally substituted with 1-5 radicals of alkyl of 1-3 carbon atoms, haloalkyl of 1-3 carbon atoms substituted with 1-7 halogen atoms, alkoxy of 1-3 carbon atoms, halogen, nitro, amino, alkylamino of 1-3 carbon atoms, amido, alkylamido of 1-3 carbon atoms, cyano, hydroxy, acyl of 2-4 carbon atoms, hydroxyalkyl of 1-3 carbon atoms, or thioalkyl of 1-3 carbon atoms; or a pharmaceutically acceptable salt thereof. view more

The method of claim 108, wherein R.sub.3 is said optionally substituted phenyl.

The method of claim 144, wherein R.sub.1 is methyl.